These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 10993223

  • 1. Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.
    Yamada T, Imai T, Ouchi K, Otagiri M, Hirayama F, Uekama K.
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1264-9. PubMed ID: 10993223
    [Abstract] [Full Text] [Related]

  • 2. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
    Acartürk F, Imai T, Saito H, Ishikawa M, Otagiri M.
    J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
    [Abstract] [Full Text] [Related]

  • 3. Solubility and mass and nuclear magnetic resonance spectroscopic studies on interaction of cyclosporin A with dimethyl-alpha- and -beta-cyclodextrins in aqueous solution.
    Miyake K, Hirayama F, Uekama K.
    J Pharm Sci; 1999 Jan; 88(1):39-45. PubMed ID: 9874700
    [Abstract] [Full Text] [Related]

  • 4. Physicochemical characterization of a new crystal form and improvements in the pharmaceutical properties of the poorly water-soluble antiosteoporosis drug 3,9-bis(N,N-dimethylcarbamoy-loxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) by solid dispersion with hydroxypropylcellulose.
    Yamada T, Saito N, Anraku M, Imai T, Otagiri M.
    Pharm Dev Technol; 2000 Jan; 5(4):443-54. PubMed ID: 11109244
    [Abstract] [Full Text] [Related]

  • 5. [Polymorphism of 3,9-bis-(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2- c]quinoline-6-one(KCA-098), a new benzofuroquinoline derivative].
    Yamada T, Ikegami K, Toda M, Saito N, Iizuka K, Otagiri M.
    Yakugaku Zasshi; 1995 Dec; 115(12):978-84. PubMed ID: 8587037
    [Abstract] [Full Text] [Related]

  • 6. Study of the interaction of clobazam with cyclodextrins in solution and in the solid state.
    Nakai Y, el-Said Aboutaleb A, Yamamoto K, Saleh SI, Ahmed MO.
    Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):728-32. PubMed ID: 2347015
    [Abstract] [Full Text] [Related]

  • 7. Heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-cyclodextrin: A water-soluble cyclodextrin derivative with low hemolytic activity.
    Hirayama F, Mieda S, Miyamoto Y, Arima H, Uekama K.
    J Pharm Sci; 1999 Oct; 88(10):970-5. PubMed ID: 10514341
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.
    Anzai K, Mizoguchi J, Yanagi T, Hirayama F, Arima H, Uekama K.
    Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1466-70. PubMed ID: 17917290
    [Abstract] [Full Text] [Related]

  • 10. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM, Elkheshen SA, Ghorab MM.
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [Abstract] [Full Text] [Related]

  • 11. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
    Al Omari AA, Al Omari MM, Badwan AA, Al-Sou'od KA.
    J Pharm Biomed Anal; 2011 Feb 20; 54(3):503-9. PubMed ID: 20971593
    [Abstract] [Full Text] [Related]

  • 12. Improvement of dissolution characteristics of psoralen by cyclodextrins complexation.
    Vincieri FF, Mazzi G, Mulinacci N, Bambagiotti-Alberti M, Dall' Acqua F, Vedaldi D.
    Farmaco; 1995 Feb 20; 50(7-8):543-7. PubMed ID: 7669193
    [Abstract] [Full Text] [Related]

  • 13. Physical properties of the complexes formed between heptakis(2,6-di-O-methyl)-beta-cyclodextrin, beta-cyclodextrin, and chlorambucil.
    Green AR, Miller ES, Guillory JK.
    J Pharm Sci; 1991 Feb 20; 80(2):186-9. PubMed ID: 2051328
    [Abstract] [Full Text] [Related]

  • 14. Study of the interaction of dithranol with heptakis(2,3,6-tri-O-methyl)-beta-cyclodextrin in solution and in the solid state.
    Cafaggi S, Vallarino M, Caviglioli G, Parodi B, Bignardi G.
    J Pharm Pharmacol; 1998 Mar 20; 50(3):257-64. PubMed ID: 9600716
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preparation of heptakis(2,6-di-O-ethyl)-beta-cyclodextrin and its nuclear magnetic resonance spectroscopic characterization.
    Hirayama F, Kurihara M, Horiuchi Y, Utsuki T, Uekama K, Yamasaki M.
    Pharm Res; 1993 Feb 20; 10(2):208-13. PubMed ID: 8384365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.